PMID

Data

Article Title

Organization

Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.

Yerkes National Primate Research Center

Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.

University Of Illinois At Chicago

Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.

Medical College Of Ohio

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

University Of Montpellier

Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.

Wyeth Research

Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.

Serono Pharmaceutical Research Institute

Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.

Merck Research Laboratories

Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide.

Merck

Oral oxytocin antagonists.

Drugmoldesign

 

Non-peptide oxytocin antagonists: identification and synthesis of a potent camphor aminosuccinimide

TBA

 

Potent, non-peptidic oxytocin receptor antagonists from a natural source

TBA

Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.

University Of Patras

Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives.

Glaxosmithkline

A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.

Université

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

Merck Research Laboratories

Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.

Merck Research Laboratories

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

Merck Research Laboratories

Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.

University Of Minnesota

Nanomolar-affinity, non-peptide oxytocin receptor antagonists.

Merck Research Laboratories

1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.

Merck Research Laboratories

A new series of photoactivatable and iodinatable linear vasopressin antagonists.

Upr 9023 Cnrs

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

Merck Research Laboratories

Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.

Merck Sharp & Dohme Research Laboratories

Orally active, nonpeptide oxytocin antagonists.

Merck Research Laboratories